12.69
0.05 (0.40%)
| Previous Close | 12.64 |
| Open | 12.64 |
| Volume | 1,694,691 |
| Avg. Volume (3M) | 2,320,288 |
| Market Cap | 1,641,931,136 |
| Price / Sales | 2.31 |
| Price / Book | 1.98 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2025 |
| Profit Margin | -11.54% |
| Operating Margin (TTM) | -16.56% |
| Diluted EPS (TTM) | -0.610 |
| Quarterly Revenue Growth (YOY) | 7.50% |
| Total Debt/Equity (MRQ) | 68.08% |
| Current Ratio (MRQ) | 2.05 |
| Operating Cash Flow (TTM) | 7.61 M |
| Levered Free Cash Flow (TTM) | -2.21 M |
| Return on Assets (TTM) | -2.75% |
| Return on Equity (TTM) | -8.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Bullish |
| Diagnostics & Research (Global) | Bullish | Bullish | |
| Stock | NeoGenomics, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -1.5 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.00 |
|
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 1.19% |
| % Held by Institutions | 98.21% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| American Capital Management Inc | 30 Sep 2025 | 2,345,263 |
| 52 Weeks Range | ||
| Median | 14.00 (10.32%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 12 Jan 2026 | 14.00 (10.32%) | Buy | 12.49 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| OLIVO ALICIA C | - | 12.93 | -15,145 | -195,825 |
| STONE WARREN | - | 12.93 | -15,127 | -195,592 |
| Aggregate Net Quantity | -30,272 | |||
| Aggregate Net Value ($) | -391,417 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 12.93 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| OLIVO ALICIA C | Officer | 13 Jan 2026 | Disposed (-) | 15,145 | 12.93 | 195,825 |
| OLIVO ALICIA C | Officer | 13 Jan 2026 | Option execute | 59,382 | - | - |
| STONE WARREN | Officer | 13 Jan 2026 | Disposed (-) | 15,127 | 12.93 | 195,592 |
| STONE WARREN | Officer | 13 Jan 2026 | Option execute | 59,382 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |